Literature DB >> 31656617

High-dose quetiapine and therapeutic monitoring.

Hervé Javelot1, Francis Rangoni2, Luisa Weiner3, Bruno Michel4.   

Abstract

Quetiapine is an atypical antipsychotic with a good safety profile permitting its administration beyond the maximum dose of 800 mg/day. We report the case of a patient with a resistant schizophrenia treated with high doses of quetiapine (up to 2000 mg/day) combined with drug monitoring and with favourable therapeutic response and tolerance. © European Association of Hospital Pharmacists 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  antipsychotics; psychiatry; quetiapine; resistant schizophrenia; therapeutic drug monitoring

Year:  2018        PMID： 31656617      PMCID： PMC6788267          DOI： 10.1136/ejhpharm-2018-001605

Source DB:  PubMed          Journal:  Eur J Hosp Pharm        ISSN： 2047-9956


  27 in total

Review 1.  Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics.

Authors:  Edoardo Spina; Christoph Hiemke; Jose de Leon
Journal:  Expert Opin Drug Metab Toxicol       Date:  2016-02-29       Impact factor: 4.481

2.  High-dose quetiapine in treatment refractory schizophrenia.

Authors:  Joseph M Pierre; Donna A Wirshing; William C Wirshing; J Michael Rivard; Russell Marks; John Mendenhall; Karen Sheppard; David G Saunders
Journal:  Schizophr Res       Date:  2005-03-01       Impact factor: 4.939

3.  World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects.

Authors:  Alkomiet Hasan; Peter Falkai; Thomas Wobrock; Jeffrey Lieberman; Birte Glenthoj; Wagner F Gattaz; Florence Thibaut; Hans-Jürgen Möller
Journal:  World J Biol Psychiatry       Date:  2012-12-06       Impact factor: 4.132

Review 4.  Pharmacokinetics of haloperidol: an update.

Authors:  S Kudo; T Ishizaki
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

5.  Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017.

Authors:  C Hiemke; N Bergemann; H W Clement; A Conca; J Deckert; K Domschke; G Eckermann; K Egberts; M Gerlach; C Greiner; G Gründer; E Haen; U Havemann-Reinecke; G Hefner; R Helmer; G Janssen; E Jaquenoud; G Laux; T Messer; R Mössner; M J Müller; M Paulzen; B Pfuhlmann; P Riederer; A Saria; B Schoppek; G Schoretsanitis; M Schwarz; M Silva Gracia; B Stegmann; W Steimer; J C Stingl; M Uhr; S Ulrich; S Unterecker; R Waschgler; G Zernig; G Zurek; P Baumann
Journal:  Pharmacopsychiatry       Date:  2018-02-01       Impact factor: 5.788

6.  Characterization of human cytochrome P450 enzymes involved in the metabolism of cyamemazine.

Authors:  Christophe Arbus; Amine Benyamina; Pierre-Michel Llorca; Franck Baylé; Norbert Bromet; Frédéric Massiere; Ricardo P Garay; Ahcène Hameg
Journal:  Eur J Pharm Sci       Date:  2007-09-14       Impact factor: 4.384

Review 7.  Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.

Authors:  Ulrich M Zanger; Matthias Schwab
Journal:  Pharmacol Ther       Date:  2013-01-16       Impact factor: 12.310

Review 8.  World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance.

Authors:  Alkomiet Hasan; Peter Falkai; Thomas Wobrock; Jeffrey Lieberman; Birte Glenthoj; Wagner F Gattaz; Florence Thibaut; Hans-Jürgen Möller
Journal:  World J Biol Psychiatry       Date:  2012-07       Impact factor: 4.132

9.  Efficacy, safety and tolerability of quetiapine: short-term high doses with long-term follow-up.

Authors:  Judit Nagy
Journal:  Int J Psychiatry Clin Pract       Date:  2005       Impact factor: 1.812

Review 10.  Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines.

Authors:  T Fukasawa; A Suzuki; K Otani
Journal:  J Clin Pharm Ther       Date:  2007-08       Impact factor: 2.512
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.